 |
市場調査レポート
商品コード
1286026
ホルモン補充療法（HRT）の世界市場：規模、シェア、成長分析－療法タイプ別、適応症別、投与経路別－産業予測（2023年～2030年）Global Hormone Replacement Therapy Market Size, Share, Growth Analysis, By Therapy Type, By Indication, By Route of Administration - Industry Forecast 2023-2030 |
||||||
| ホルモン補充療法（HRT）の世界市場：規模、シェア、成長分析－療法タイプ別、適応症別、投与経路別－産業予測（2023年～2030年） |
|
出版日: 2023年04月22日
発行: SkyQuest
ページ情報: 英文 165 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のホルモン補充療法（HRT）の市場規模は、2021年に249億7,000万米ドルとなり、2022年の268億7,000万米ドルから、2030年には492億5,000万米ドルになると予測されています。2023年から2030年までの予測期間中のCAGRは7.83%となっています。コレステロール値の上昇、血栓、膨満感、腫れなどの問題を含む副作用の可能性が、市場の成長を抑制しています。
当レポートでは、世界のホルモン補充療法（HRT）市場について調査しており、市場概要、市場分析、企業プロファイルなど、包括的な情報を提供しています。
目次
エグゼクティブサマリー
親市場分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 主要な市場洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- 知財分析
- 貿易分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資分析
- 主要な成功要因
- 競合の程度
- 市場力学と展望
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制状況
- ポーターの分析
- 競争企業間の敵対関係
- 代替製品の脅威
- 買い手の交渉力
- 新規参入業者の脅威
- 供給企業の交渉力
- 将来の混乱に関するSkyquestの特別な洞察
- 政治的影響
- 経済的影響
- 社会的影響
- 技術的影響
- 環境的影響
- 法的影響
- 世界のホルモン補充療法（HRT）市場：療法タイプ別
- 市場概要
- エストロゲン・併用補充療法
- 甲状腺ホルモン補充療法
- 成長ホルモン補充療法
- テストステロンホルモン補充療法
- 世界のホルモン補充療法（HRT）市場：適応症別
- 市場概要
- 閉経
- 甲状腺機能低下症
- 男性の性腺機能低下症
- 成長ホルモン欠乏症
- 世界のホルモン補充療法（HRT）市場：投与経路別
- 市場概要
- 経口
- 経皮
- 非経口
- 世界のホルモン補充療法（HRT）市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ
- 競合情勢
- 主要5社の比較
- 主要企業の市場でのポジショニング（2021年）
- 主要な市場参入企業が採用した戦略
- 主要成功戦略
- 開発別
- 企業別
- 年別
- 市場における最近の活動
- 主要企業の市場シェア（%）（2021年）
- 主要な企業プロファイル
- Eli Lilly and Company（米国）
- Bayer AG（ドイツ）
- Pfizer Inc.（米国）
- Viatris, Inc.（米国）
- Novo Nordisk A/S
- Novartis International AG
- Merck & Co. Inc.
- Mylan N.V.
- TherapeuticsMD Inc.
- Abbott Laboratories
- Allergan plc
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc.
- AbbVie Inc.
- Ferring Pharmaceuticals
- GlaxoSmithKline plc
- Johnson & Johnson
- Ipsen S.A.
- Sanofi S.A.
Hormone Replacement Therapy (HRT) Market size was valued at USD 24.97 billion in 2021 and is poised to grow from USD 26.87 billion in 2022 to USD 49.25 billion by 2030, growing at a CAGR of 7.83% in the forecast period (2023-2030).
For many years, women with menopause-related disorders have been successfully treated with hormone replacement therapy. As a result, the risk of osteoporosis has decreased, as have other menopause symptoms including hot flashes. Due to the development in additional hormone-related ailments that are targeted at different age groups and affect both women and men, these therapies are also causing the market to grow. Therefore, it is anticipated that over the projection period, conditions like thyroid disorders, growth deficits, and others would speed up market expansion on a global scale.
The hormone replacement therapy (HRT) industry is growing as a result of factors like the availability of long-acting hGH products and the rising prevalence of target disorders. According to the American Thyroid Association, thyroid disease will affect 12% of Americans at some point in their lives. Furthermore, it mentioned that roughly 20 million Americans have thyroid illness. According to numerous studies, people on HRT presumably had a low risk of COVID-19 infection and mortality.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hormone Replacement Therapy (HRT) Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report:
Global hormone replacement therapy (HRT) market is segmented based on therapy type, indication and region. Based on therapy type, the market is segmented into estrogen & combinations replacement therapy, thyroid hormone replacement therapy, growth hormone replacement therapy, testosterone hormone replacement therapy segments. On the basis of indication, the market can be bifurcated into menopause, hypothyroidism, male hypogonadism, growth hormone deficiency segments. Based on the route of administration, the market is segregated into oral, transdermal and parenteral route segments. The regional insights of the market are into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa.
Driver
People with growth hormone deficiency, menopausal symptoms in women, and hypogonadism in the elderly are among the many people who require the therapy. The drug is available in a variety of forms, such as skin and buccal patches, injections, tablets, and others. Producers are focusing on developing innovative medicine delivery systems, such as transdermal oestrogen patches and vaginal oestrogen pills, as a result of the rising use of these products around the world. In line with the safety worries, they are focusing more on the introduction of low dose oestrogen therapy than high dose oestrogen therapy. The key competitors in the global market have also embraced the launch of gel-based formulations for items like oestrogen patches.
Restraint
Market expansion is being negatively impacted by some issues. Patches, gel, pills, and injections are just a few of the several therapeutic formulations available. However, these medications' possible adverse effects, which include an increase in cholesterol levels, blood clots, bloating, swelling, and other issues, may limit market growth.
Additionally, it is projected that the adverse effects of testosterone replacement therapy, such as benign prostatic hyperplasia, obstructive sleep apnea, and prostate cancer, may restrain market growth. Due to the rise in cardiovascular disorders among patients undergoing testosterone replacement therapy, the US FDA has also expressed concern regarding the approved indication and the increasing incidences of cardiovascular risks associated with the products used in testosterone replacement therapy.
Market Trends
The growth in unmet demand for hormone replacement therapy in emerging countries and the greater awareness of the treatment of hormone issues are driving pharmaceutical companies to continuously bring new cutting-edge pharmaceuticals to the global market. In addition, the prevalence of menopause and diseases linked to hormone deficiency in developed countries has led manufacturers to develop new products such combination treatment solutions in place of the long-acting parenteral drugs that were formerly used daily.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Global Hormone Replacement Therapy (HRT) Market by Therapy Type
- Market Overview
- Estrogen & Combinations Replacement Therapy
- Thyroid Hormone Replacement Therapy
- Growth Hormone Replacement Therapy
- Testosterone Hormone Replacement Therapy
- Global Hormone Replacement Therapy (HRT) Market by Indication
- Market Overview
- Menopause
- Hypothyroidism
- Male Hypogonadism
- Growth Hormone Deficiency
- Global Hormone Replacement Therapy (HRT) Market by Route of Administration
- Market Overview
- Oral
- Transdermal
- Parenteral
- Global Hormone Replacement Therapy (HRT) Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- TherapeuticsMD Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ferring Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
